ArticleClinical parkinsonism & related disorders2026
An unusual case of Pisa syndrome secondary to anti-IgLon 5 disease.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pisa syndrome, characterized by lateral flexion of the trunk, is most often associated with neuroleptic use or neurodegenerative disorders like Parkinson's disease. Anti-IgLON5 disease is a rare neuroimmunological condition with overlapping features of autoimmunity and tauopathy, manifesting with sleep and cognitive disturbances, bulbar symptoms, and movement disorders. We report a 50-year-old man who presented with progressive lateral trunk flexion, head drop, dysarthria, and choreiform movements. The classic features of antiIgLon 5 disease including sleep and cognitive disturbances were absent. Serum testing confirmed strong positivity for anti-IgLON5 antibodies. Treatment with rituximab led to marked clinical improvement, with amelioration of symptoms at 24 months. This case illustrates an uncommon presentation of anti-IgLON5 disease as Pisa syndrome. Recognition of this association is important, as early immunotherapy can significantly improve outcomes in an otherwise progressive and disabling condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.